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Objectives: In patients at risk of hypoxic ischemic brain injury following cardiac arrest, we 
sought to (i) characterize brain oxygenation and determine the prevalence of brain hypoxia, (ii) 
characterize autoregulation using the pressure reactivity index (PRx) and identify the optimal 
mean arterial pressure (MAPOPT), and (iii) assess the relationship between MAPOPT and brain 
tissue oxygenation (PbtO2). 
Design: Prospective interventional study. 
Setting: Quaternary intensive care unit. 
Patients: Adult patients with return to spontaneous circulation (ROSC) greater than 10 minutes 
and a post-resuscitation Glasgow Coma Score under 9 within 72 hours of cardiac arrest.  
Interventions: All patients underwent multimodal neuromonitoring which included: (i) PbtO2, 
(ii) intracranial pressure; (iii) jugular venous continuous oximetry (SjvO2); (iv) regional 
saturation of oxygen (rSO2) using near-infrared spectroscopy, and (iv) PRx based determination 
of MAPOPT, lower and upper limit of autoregulation.  We additionally collected MAP, end tidal 
carbon dioxide (ETCO2) and temperature.  All data were captured at 300 Hz using ICM+® brain 
monitoring software.   
Measurements and Main Results: Ten patients (7 males) were included with a median age 47 
(range 20 – 71) and ROSC 22 minutes (12 – 36).  The median duration of monitoring was 47 
hours (15 - 88) and median duration from cardiac arrest to inclusion was 15 hours (6 - 44). The 
mean PbtO2 was 23 mmHg (SD 8) and the mean percentage of time with a PbtO2 below 20 
mmHg was 38% (6 – 100).  The mean PRx was 0.23 (0.27) and the percentage of time with a 
PRx greater than 0.3 was 50% (12 – 91).  The mean MAPOPT, lower and upper of autoregulation 
were 89 mmHg (11), 82mmHg (8) and 96 mmHg (9), respectively.  There was marked between-
patient variability in the relationship between MAP and indices of brain oxygenation.  As the 
patients’ actual MAP approached MAPOPT, PbtO2 increased (p<0.001).  This positive 
relationship did not persist when the actual MAP was above MAPOPT.  
Conclusions:  Episodes of brain hypoxia in HIBI are frequent and perfusion within proximity of 
MAPOPT is associated with increased PbtO2.  PRx can yield MAPOPT, lower and upper limit of 








  The pathophysiology of hypoxic ischemic brain injury (HIBI) emanates from a primary 
insult during cardiac arrest and secondary injury that results partially from an inadequate balance 
between cerebral oxygen delivery (CDO2) and utilization following return of spontaneous 
circulation (ROSC)(1).  Secondary injury is increasingly recognized as a significant determinant 
of neurological outcome, and mitigating its deleterious effects is a mainstay of post cardiac arrest 
management (1, 2).   
Following ROSC, brief hyperemia is followed by prolonged hypoperfusion, termed ‘no-
reflow’ (1, 3, 4) which causes inadequate CDO2 and secondary injury (1, 5).  Observational 
studies demonstrate that perturbations in CDO2 from hypotension (6, 7) and hypocapnia (8) after 
ROSC during no-reflow are associated with worse neurological outcome.  Animal models have 
confirmed the no-reflow phenomenon (9) and demonstrate that increasing CDO2 with mean 
arterial pressure (MAP) augmentation results in improved thalamic and subcortical brain tissue 
oxygenation (PbtO2) (10, 11).  A recent systematic review suggests increased MAP is associated 
with improved neurologic outcome following cardiac arrest (12).  Intuitively, uniform MAP 
augmentation seems like a plausible therapeutic intervention, however, a ‘one size fits all’ 
approach fails to account for individual physiologic differences between patients and may expose 
patients to adverse effects of exogenous vasopressors.  Hence, recent efforts have been targeted 
at identifying personalized perfusion targets in HIBI (13).  
Cerebral autoregulation is the inherent capacity of the cerebrovasculature to undergo 
cyclical cerebral vasoconstriction and vasodilation to protect the brain from ischemia and 
hyperemia (14), respectively.  In health, cerebral autoregulation maintains stable cerebral blood 
flow (CBF) over a wide range of MAP(14–16).  After cardiac arrest, the preserved range of 
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autoregulation is often narrowed and right shifted (17).  Pressure reactivity index (PRx), a 
moving Pearson’s correlation coefficient between MAP and intracranial pressure (ICP), can 
monitor autoregulation in real time and identify individualized MAP thresholds after brain injury 
(18).  Importantly, PRx is an indirect measure of autoregulation.  Fluctuations in MAP will lead 
to either cerebral vasoconstriction or vasodilation with resultant subsequent changes in 
cerebrovascular blood volume and therefore ICP.  Dysfunctional autoregulation is characterized 
by a positive correlation between MAP and CBF, owing to pressure passive vasodilation of the 
cerebrovasculature (19).  Increased CBF results in increased cerebrovascular volume which itself 
leads to elevated ICP (20).  With intact autoregulation, increasing MAP is countered by 
vasoconstriction, which reduces cerebrovascular blood volume and ICP, thereby producing a 
negative or near zero PRx (19).  By plotting PRx against MAP, a U-shaped curve is formed with 
the nadir denoted as the optimal MAP (MAPOPT) (21).  After traumatic brain injury, perfusion 
within 5 mmHg of the optimal cerebral perfusion pressure results in improved PbtO2 (22) and 
improved neurological outcome (21).  It is unknown whether proximity to MAPOPT results in 
improved PbtO2 in humans with HIBI.   
As such, we conducted a prospective study of invasive neuromonitoring in patients with 
HIBI.  The objectives of our study were: (1) characterize PbtO2 and brain hypoxia over time and 
its relationship to MAP, (2) characterize cerebral autoregulation as assessed by PRx over time, 
(3) characterize MAPOPT, Lower Limit of Autoregulation (LLA) and Upper Limit of 
Autoregulation (ULA) over time, (4) determine the relationship between the difference in 
patients’ actual MAP and MAPOPT (termed MAP difference [MAPDIFF]) and PbtO2, (5) 
characterize the relationship between both PbtO2 and PRx and two potential confounders – 




 We conducted a prospective study in 10 patients following cardiac arrest with HIBI using 
multimodal neuromonitoring.  The University of British Columbia Clinical Research Ethics 
Board approved the study (August 23, 2016 - H16-00466) and written informed consent was 
obtained from the temporary substitute decision maker.  The study was registered at 
clinicaltrials.gov (NCT03609333).   
Study population and hospital 
 The Vancouver General Hospital intensive care unit (ICU) is a quaternary closed 34 bed 
mixed medical-surgical unit affiliated with the University of British Columbia.  The ICU 
provides quaternary neurotrauma care for the province of British Columbia and conducts 
invasive multimodal neuromonitoring in approximately 40 neurologically injured patients 
annually.   
 Patients were included if they sustained a cardiac arrest and fulfilled the following 
criteria: 1) time to ROSC of greater than 10 minutes with greater than 20 minutes of sustained 
circulation, 2) post ROSC un-confounded Glasgow coma score of less than 9, and 3) inclusion 
within 72 hours of cardiac arrest.  We excluded patients who had any of the following criteria: 1) 
concurrent coagulopathy (INR > 1.5, prothrombin time > 40 seconds, platelet count < 100 x 
109/L), 2) likely cardiac catheterization within 7 days, 3) current or anticipated anticoagulant or 
antiplatelet therapy during the study period, 4) therapeutic hypothermia targeting a temperature 
under 35oC, 5) prior history of severe TBI, intracranial hemorrhage or stroke, 6) anticipated 
withdrawal of life-sustaining therapy within 72 hours.   
Neurophysiologic Monitoring & Data Collection 
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ICP (Camino®, Integra Lifesciences, New Jersey, USA) and PbtO2 (Licox®, Integra 
Lifesciences, New Jersey, USA) catheters were inserted through a dual lumen bolt in the non-
dominant frontal lobe by the attending neurosurgeon or designate.  We also inserted a continuous 
oximetric jugular venous bulb (SjvO2) catheter (Pediasat®, Edwards Lifesciences, USA).  The 
SjvO2 catheter was placed in the dominant internal jugular vein identified by ultrasonography, 
and positioned at the level of the mastoid process on skull base x-ray.  Near-infrared 
spectroscopy (NIRS) pads (INVOS®, Medtronic, Minneapolis, MN, USA) were affixed to the 
forehead bilaterally.  The following data were recorded at 300 Hz using ICM+® brain 
monitoring software (Cambridge Enterprise, United Kingdom): ICP, MAP, PbtO2, rSO2, SjvO2, 
temperature, and ETCO2).  
 We also collected information relating to the cardiac arrest: etiology of the cardiac arrest, 
initial rhythm, whether the arrest was witnessed or unwitnessed, administration of bystander 
cardiopulmonary resuscitation, duration until ROSC, doses of epinephrine administered, and 
number of defibrillation attempts.  We also collected multiple daily arterial blood gas samples. 
We defined brain tissue hypoxia as a PbtO2 below 20 mmHg, as extrapolated from 
patients with traumatic brain injury (23, 24).  We defined dysfunctional cerebral autoregulation 
as a PRx greater than 0.3 (14).  Neurologic outcomes were recorded at 6 months by telephone 
interview using the Glasgow Outcome Scale: (1) death, (2) persistent vegetative state, (3) severe 
disability - conscious but disabled, (4) moderate disability – independent for daily activities but 
with disabilities, and (5) good recovery – normal activities although may have minor deficits.  
An independent intensive care physician reviewed each subject to assess for any complications 




 Our ICU uses targeted temperature management guideline for post cardiac arrest care of 
patients with HIBI targeting a goal temperature of 36oC using external surface cooling 
techniques and anti-pyrexial medications.  Core body temperature is monitored using a 
continuous esophageal, rectal or urinary bladder temperature probe.  Patients are sedated with 
intravenous propofol infusions during targeted temperature management and hemodynamic 
targets are set in accordance with international guidelines at the attending physician’s 
discretion(25).  All patient care decisions were left to the discretion of the attending physician 
and they were allowed to use the neuromonitoring data for clinical decisions as per usual 
practice. 
Our ICU uses a tier based algorithm in patients with multimodal neuromonitoring in situ 
which utilizes increasing intensity of therapy aimed at keeping ICP < 25 mmHg and with 
titration of MAP / CPP to target PbtO2 > 20 mmHg (26) using intravenous norepinephrine as the 
primary vasopressor.  Strict adherence to arterial normoxemia (PaO2 80 to 100mmHg) was 
maintained for the duration of the monitoring period in each study subject to allow delineations 
of the physiologic relationships with PbtO2.  
Statistical Analysis 
A sample of 10 was chosen as the number of patients we could enroll within the time 
available for the study.  Data collected by ICM+® brain monitoring software were exported at 
10-sec averaged values into Microsoft Excel (Redmond, WA, USA).  The data were then 
subsequently imported into Stata 15.0 (StataCorp, Texas, USA), which was used for all analyses.  
ICM+® software calculates PRx in real-time as a moving Pearson correlation coefficient 
between 30 consecutive, 10 s averaged values of MAP and ICP signals(27).  MAPOPT is 
determined as a secondary derivative by plotting PRx (y-axis) against the MAP range (x-axis) in 
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5 mmHg bins.  An automatic multi-window curve-fitting methodology was used to estimate 
MAPOPT (OptimalValueFlex function in ICM+).  The LLA and ULA were also determined using 
this methodology (28), adopting a PRx optimal threshold of 0.25.  We calculated the difference 
between actual MAP and MAPOPT for each time point MAPDIFF.  We then collapsed the 10-
second data over 10-minutes using mean values.  All analyses were two-sided and we considered 
p<0.05 to be statistically significant.  
Characterization of brain oxygenation and hypoxia over time and its relationship to 
MAP.  PbtO2 and MAP were first assessed visually by plotting both over time for each 
individual. To characterize the degree of brain tissue hypoxia, we calculated the number of 10-
minute periods where PbtO2 was below 20 mmHg for each individual.  In order to estimate the 
average profiles of PbtO2 and MAP over time, we fitted a linear mixed model specifying 
‘patient’ as a random-effect (STATA command xtreg) to account for the within-subject 
correlation of the data structure.   
We then visually assessed the relationship of each variable of brain hypoxia (PbtO2, rSO2 
and SjvO2) by plotting each against MAP. We overlaid the scatterplot with ten locally weighted 
scatterplot smooths, one for each individual. For each measure of brain hypoxia (PbtO2, rSO2 
and SjvO2) we fit a linear mixed model that included MAP as a fixed effect and ‘patient’ as a 
random effect (STATA command xtreg). For modelling, we calculated the marginal and 
conditional R2 as a measure of the variance explained. 
Characterization of cerebral autoregulation (PRx) over time.  We plotted PRx over time 
for each individual.  We determined average PRx by 10-minute periods to determine the 




Characterization of MAPOPT, LLA and ULA over time and the relationship between 
MAPDIFF and PbtO2.  We first plotted MAPOPT, LLA and ULA over time.  In order to link brain 
tissue oxygenation to cerebral autoregulation, we sought to assess the relationship between PbtO2 
and MAPDIFF, which is a measurement of how far away the patients actual MAP is from their 
MAPOPT. One would expect that PbtO2 would be low when MAPDIFF is below zero.  We plotted 
PbtO2 vs. MAPDIFF for each patient and overlaid the scatterplot with ten locally weighted 
scatterplot smooths, one for each individual.  Because of the non-linear relationship between 
PbtO2 and MAPDIFF, we modelled this relationship using fractional polynomial regression 
specifying ‘patient’ as a random-effect.  To numerically describe this relationship, we calculated 
the mean (SD) of PbtO2 stratified by quartiles of MAPDIFF. 
Characterize the relationship between both PbtO2 and PRx with temperature and end-
tidal carbon dioxide (ETCO2).  We plotted PbtO2 and PRx against temperature and ETCO2 and 
overlaid the scatterplot with ten locally weighted scatterplot smooths for each individual.   
As part of an exploratory analysis, we compared PRx in survivors and non-survivors and how 
this changed over time.  This latter analysis was performed by fitting a linear mixed model 
specifying ‘patient’ as a random-effect (STATA command xtreg) and included an interaction 




                                                                       Results 
 Twenty-two consecutive patients were screened between November 2016 and January 
2018, of which 10 met inclusion criteria and were enrolled.  Individual demographics of the 
patients are shown in Table 1.  The median age of the cohort was 47 and seven were male.  The 
initial rhythm was pulseless electrical activity in 9 patients and 1 patient had ventricular 
fibrillation.  The median duration from time of cardiac arrest to insertion of multimodal 
neuromonitoring was 15 hours and the median duration of multimodal monitoring was 47 hours.  
Over the entire cohort and duration of monitoring the mean (SD) of MAP, ICP and CPP were 88 
(15) mmHg, 14 (15) mmHg and 75 (7) mmHg, respectively.  The mean ETCO2 was 32 (6) 
mmHg and mean core body temperature was 35.7 oC (0.8).  There were no serious adverse events 
related to the monitoring (intracranial hemorrhage or infection) during or after the study period. 
Characterization of brain oxygenation and hypoxia over time and relationship to MAP.  
The mean PbtO2 in the entire cohort was 23 (8) mmHg.  Of the 1944 10-minute averaged 
periods, 743 (38%) had a PbtO2 under 20 mmHg.  On an individual patient level, the mean 
percentage of time that patients in the cohort experienced a PbtO2 under 20 mmHg was 38% 
(range 6 – 100).  During the study period, the mean rSO2 was 67 (14) % and mean SjvO2 was 
74% (11).  Relationships between PbtO2 and MAP in individual patients over time during the 
monitoring period are presented in Figure 1.  Both PbtO2 (0.20 mmHg, 95% CI: 0.18 – 0.22) and 
MAP (0.16 mmHg, 95% CI: 0.12 – 0.19) increased per hour during the monitoring period.  
Figure 2 demonstrates the relationship between MAP and indices of oxygenation.  MAP was 
linearly related to both PbtO2 and SjvO2 but not rSO2.  The large difference between the 
conditional and marginal R2 values observed indicates marked between-patient variability in the 
effects of MAP on the indices of oxygenation.      
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Characterization of cerebral autoregulation (PRx) over time.  The overall mean PRx was 
0.23 (0.27).  Out of the 2409 10-minute averaged PRx measurements, 1148 (48%) were greater 
than 0.3.  On an individual patient level, the median percentage of time with a PRx of greater 
than 0.30 was 50% (range 12 – 91).  Figure 3 presents the change of PRx over time for each 
patient.   
Characterization of MAPOPT, LLA and ULA over time and determine the relationship 
between MAPDIFF and PbtO2.  The mean (SD) MAPOPT, LLA and ULA were 89 (11) mmHg, 82 
(8) mmHg and 96 (9) mmHg, respectively.  MAPOPT, LLA and ULA over time are presented for 
each patient in Figure 4.  The median time spent of actual MAP within 5 mmHg of MAPOPT was 
42% (range 10 – 78).  The percentage of time spent below -5 mmHg was 32% (range 12 – 74) 
and above +5 mmHg from the MAPOPT was 27% (range 4 – 54).  Please see the eTable 1 for 
mean values of MAP, ICP, CPP, PRx, MAPOPT, LLA, ULA, ETCO2 and temperature over time 
during the monitoring period.  
In order to link brain tissue oxygenation and cerebral autoregulation, we assessed the 
relationship between relationship between PbtO2 and MAPDIFF (Figure 5).  Fractional polynomial 
regression demonstrated a non-linear relationship between PbtO2 and MAPDIFF (p<0.001).  PbtO2 
increased as the difference between MAP and MAPOPT approached zero.  PbtO2 leveled off as 
MAPDIFF went above zero.  To numerically describe this relationship, we divided MAPDIFF into 
quartiles and calculated the associated PbtO2.  Quartile 1 (MAPDIFF ≤ -5mmHg) had a mean 
PbtO2 of 19 (9) mmHg; quartile 2 (MAPDIFF -4 to 2 mmHg) had a mean PbtO2 of 25 (9) mmHg; 
quartile 3 (MAPDIFF  2 to 9 mmHg) had a mean PbtO2 of 23 (10) mmHg; and quartile 4 
(MAPDIFF > 9 mmHg) had a mean PbtO2 of 26 (9) mmHg.   
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Visually, there did not appear to be any relationship between either PbtO2 (eFigure 1) or 
PRx (eFigure 2) and temperature or ETCO2.  
As part of an exploratory analysis, we compared PRx over time in survivors and non-
survivors.  The mean PRx was 0.31 (SD 0.19) in survivors and 0.16 (SD 0.32) in non-survivors.  
There were several patterns that emerged when visually inspecting PRx over time.  Survivors 
appeared to either have improving (Figure 3, patients 3 & 5) or preserved (Figure 3, patients 1 & 
9) autoregulation.  Non-survivors appeared to have dysfunctional (Figure 3, patient 2 & 4) or 
worsening (Figure 3, patient 4 & 10) autoregulation.  In non-survivors, the PRx increased each 
hour by 0.0052 (95%CI: 0.0032 to 0.0071) whereas in survivors, PRx decreased over each hour 
by -0.0078 (95%CI: -0.0090 to -0.0065) (p-interaction <0.001).   
 





 We present the first prospective study using invasive multimodal neuromonitoring to 
evaluate brain hypoxia and cerebral autoregulation using PRx in patients with HIBI.  Overall, 
there was a significant burden of brain hypoxia demonstrated in our cohort.  Although there was 
a linear relationship between PbtO2 and SjvO2 with MAP, there was marked between-patient 
variability.  We were also able to characterize cerebral autoregulation using PRx and identify 
MAPOPT, LLA and ULA.  Interestingly, the overall mean MAPOPT was 89 mmHg which is 
markedly higher than recommended by international guidelines (29).  Finally, we found an 
association between perfusion within proximity of PRx derived MAPOPT and PbtO2.  PbtO2 
improved when the actual MAP approached within 10 mmHg of MAPOPT, suggesting improved 
CDO2 within proximity to MAPOPT. 
 It is increasingly evident that secondary injury leads to adverse neurologic outcome and 
identification of ongoing brain hypoxia after ROSC is imperative.  Human studies have 
principally focussed on establishing links between decreased rSO2 as a surrogate marker of brain 
oxygenation and neurological outcome, but have yielded conflicting results in its predictive 
utility (30–33).  These conflicting results, along with technical limitations of NIRS have 
hindered its routine use in evaluating brain hypoxia post cardiac arrest.  We present the first 
prospective study evaluating the burden of brain hypoxia using a direct invasive measure of 
cerebral oxygenation in post cardiac arrest patients with HIBI.  Our results demonstrating a 
significant burden of brain hypoxia in our cohort during the ‘no reflow’ period are in keeping 
with prior physiologic and animal studies confirming the presence of oligemic CBF, brain 
hypoxia and neuronal ischemia after ROSC (29-31).  Eight of ten subjects in our study exhibited 
an initial PbtO2 < 20mmHg (figure 1) indicating that we may have captured the cerebrovascular 
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physiologic profile in these subjects during ‘no reflow’.  Importantly, the median duration from 
time of cardiac arrest to data collection was 15 hours in our study, a timeline that is relatively 
late in the ‘no reflow’ period when the resolution of reduced CBF and CDO2 would be expected.  
As such, it is possible that the burden of brain hypoxia may be underestimated in our study.   
Delineating the significance of brain tissue hypoxia as a modifiable factor, as opposed to 
an expected epiphenomenon in the natural history of HIBI, is essential.  In animal models, MAP 
augmentation using exogenous vasopressors has demonstrated improved PbtO2 in thalamic and 
cortical tissue, structures which are exquisitely susceptible to secondary injury (9, 11).  We also 
observed a relationship between MAP and PbtO2 in individual patients over time.  Although 
significant, the variation of this relationship within patients could be explained by numerous 
factors including simultaneous fluctuations in other physiologic variables such as ETCO2, 
temperature and hemoglobin.  As part of the study protocol, attending physicians were able to 
manipulate multiple physiologic variables to achieve PbtO2 > 20mmHg and hence, we are unable 
to imply causality to augmented MAP and increased PbtO2. We also sought to delineate the 
relationships between MAP and non-invasive measures of CDO2, namely rSO2 and SjvO2.  We 
did observe a significant association between increasing MAP and SjvO2, but this relationship 
was less robust than the relationship between MAP and PbtO2.  As opposed to PbtO2, which is 
principally determined by CBF in the setting of stable PaO2, SjvO2 is additionally dependent 
cerebral metabolic rate and arterial oxygen content (35).  These were not held constant in our 
study.  We did not find a relationship between MAP and rSO2, raising doubts as to the validity of 
rSO2 by itself to monitor cerebral perfusion in HIBI.  NIRS has been advocated as a surrogate 
measure of CBF and CDO2 during cardiopulmonary resuscitation and in identifying early ROSC 
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(36), however, data is lacking in establishing rSO2 as a reliable estimator of CBF beyond the 
immediate post ROSC period.   
Our results are consistent with epidemiologic data which suggests that post-ROSC 
hypotension may contribute to worse  neurologic outcomes (6).  A systematic review of studies 
examining MAP thresholds in patients following cardiac arrest demonstrated that increased MAP 
targets were associated with improved neurologic outcomes (12).  Although generalized 
increased MAP targets post cardiac arrest may be a viable therapeutic intervention, the ‘one size 
fits all’ approach fails to account for physiological differences between patients.  Furthermore, 
uniform MAP augmentation using vasopressors carries significant risks, including increased 
afterload on decompensated left ventricular function, arrhythmias, and mesenteric or limb 
ischemia.  Therefore, an individualized approach to MAP targets in HIBI patients has emerged as 
an attractive area of research (13). 
The mean MAPOPT observed in our study (89 mmHg) is higher than international post 
cardiac arrest guidelines which recommend MAP > 65 mmHg (29).  Importantly, there was 
considerable between and within-patient MAPOPT variability which further highlights the 
heterogeneous nature of HIBI.  This marked heterogeneity may serve as an opportunity to 
therapeutically target individual MAP thresholds in patients with HIBI (13), rather than the 
current uniform approach.  In particular, we found that cerebral autoregulation, as assessed by 
PRx, changes over time.  Our data also suggests that the change in PRx over time may differ 
between survivors and non-survivors, although more data is clearly needed to elucidate this 
relationship.  The relative importance of MAPOPT versus LLA and ULA remain unclear.  It may 
be that LLA is a crucial physiologic parameter to target as thresholds below LLA are associated 
with cerebral oligemia and brain hypoxia (37).  Importantly, the mean LLA (82 mmHg) in our 
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cohort was also still markedly higher than post cardiac arrest guidelines for MAP > 65 mmHg.  
The importance of LLA and ULA as perfusion targets in HIBI requires further research.  
Our results are also consistent with a prior study using transcranial Doppler to assess 
cerebral autoregulation in patients following cardiac arrest which demonstrated a right shifted 
lower limit of autoregulation using transcranial Doppler (38).  Furthermore, Ameloot et al. 
retrospectively calculated COx, a correlation coefficient between MAP and  the rSO2 from NIRS 
to characterize autoregulation and found the  mean MAPOPT in their cohort to be 85 mmHg (39).  
Using a similar, but prospective COx based assessment of cerebral autoregulation, our research 
group recently observed a mean MAPOPT to be 76 mmHg in a cohort of post cardiac arrest 
patients using COx (40).   
We attempted to assess the physiologic relationship between MAPOPT and CDO2, as 
measured by PbtO2.  Despite heterogeneity between patients, there appeared to be a non-linear 
relationship between MAPDIFF and PbtO2.  When the actual MAP was more extreme than -10 
mmHg below MAPOPT, there was a linear rise of PbtO2 as MAPDIFF approached -10 mmHg.   
Between MAPDIFF of -10 to +10 mmHg, there was a less steep rise in PbtO2, with this relationship 
becoming more attenuated at the top of this range.  MAPDIFF above +10 mmHg was not 
associated with further improvements in PbtO2.  This relationship highlights that perfusion 
within proximity of MAPOPT is associated with improved PbtO2 and its physiologic significance 
must be further evaluated.  Importantly, perfusion beyond the MAPOPT was not associated with 
increasing PbtO2, thereby suggesting that uniformly increased MAP targets will unreliably lead 
to improved PbtO2 and could simply expose patients to the harmful effects of unnecessary 
exogenous vasopressors.  Similar findings have been observed in patients with traumatic brain 
injury where Jaeger et al. demonstrated that PbtO2 increased significantly as actual CPP 
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approached optimal CPP derived from PRx (41).  These findings were further corroborated with 
a physiologic study revealing that perfusion pressures associated with negative PRx (intact 
autoregulation) were associated with improved CDO2, cerebral oxygen metabolic rate and 
cerebral blood flow (42).  In traumatic brain injury, the clinical significance of these observed 
physiologic benefits are illustrated as deviation of actual CPP from the optimal CPP is associated 
with worse long term neurological outcomes (21).  We found over half of the actual MAP 
measurements were more than 5 mmHg from MAPOPT, suggesting an opportunity for future 
interventional research to target adherence to MAPOPT.   
 Our study is novel and characterizes the cerebrovascular pathophysiological sequelae of 
HIBI after cardiac arrest.  Strengths of our study include the high granularity of data collection 
(300Hz) with time-stamped neurophysiologic variables to facilitate examining the underlying 
relationships between various measures of brain oxygenation and CDO2.  We gathered 
considerable longitudinal data over time with a mean duration of monitoring during the study of 
46 hours and were able to evaluate the physiological profile of a key determinant of CDO2 
(MAP) on brain oxygenation in HIBI.  Finally, we demonstrated improved PbtO2 within 
proximity of MAPOPT, raising the possibility of beneficial targeted individualized perfusion 
targets in HIBI, however, this concept requires significant further physiologic and clinical 
delineation. 
Our study has important limitations. Our small sample size limits our ability to draw firm 
conclusions on HIBI pathophysiology and indeed suggests that there are likely distinct HIBI 
phenotypes.  This is particularly important when trying to examine for other factors that may 
confound the relationship between MAP and PbtO2, namely ETCO2 and temperature.  This is the 
first study of its kind and necessarily is exploratory and hypothesis-generating in nature, we are 
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unable to imply causal associations between MAP and MAPOPT with assessments of brain 
oxygenation.  Instead, the observed associations in our study are intended to provide further 
justification to delineate their clinical and physiological significance in the future. Secondly, our 
definition of brain hypoxia (PbtO2 < 20mmHg) is extrapolated from traumatic brain injury 
literature (24) and may not reflect an important threshold in patients in HIBI.  Owing to the 
reduced cerebral metabolic demand immediately after cardiac arrest, patients with HIBI may 
tolerate lower levels of PbtO2 (43).  Establishing HIBI specific PbtO2 thresholds in humans of 
brain hypoxia against gold standard assessments of CDO2 such as positron emission scanning is 
an essential gap in the current literature. In addition, the observed relationship between MAP and 
PbtO2 does not reflect the end organ balance of aerobic versus anaerobic metabolism.   
We used PRx as a measure of autoregulation, however, we acknowledge that PRx is an 
indirect estimator of dynamic autoregulation which relies upon repeated longitudinal integration 
between fluctuations in values of MAP and changes in CBF / cerebrovascular blood volume and 
downstream ICP fluctuations.  Dynamic changes in CBF may occur from alternative physiologic 
stressors independent from MAP including changes in arterial carbon dioxide tension, cerebral 
metabolic rate and temperature fluctuations, thereby negating the accuracy of PRx.  We 
attempted to control these variables in our study by mandating strict PaCO2 35 to 40mmHg, 
targeted temperature management (36oC) and intravenous sedation using propofol to target burst 
suppression during the study period.  However, it is possible that such goals were uniformly 
achieved and have affected our results. 
Importantly, the patients in our cohort primarily underwent cardiac arrest from pulseless 
electrical activity secondary to underlying causes that likely resulted in pre-circulatory arrest 
cerebral ischemia (hemorrhage, hypoxia) as opposed to primary sudden cardiac arrest from 
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arrythmias.  As such, our results must be interpreted under premise that the majority of patients 
in our cohort likely fall on the severe end of the HIBI pathophysiology spectrum.  Therefore, our 
results should not be extrapolated to patients with sudden cardiac arrest from arrythmias who 
undergo immediate cardiopulmonary resuscitation and further work is needed to delineate the 
pathophysiology in this sub-population. 
Finally, increased MAP also may not translate into definitively increased CBF as we did 
not account for changes in cerebrovascular resistance.  Future steps of study in this disease 
should evaluate direct measures of CBF as well as measures of cerebral metabolism using 
cerebral microdialysis and positron emission scanning.   
 
Conclusion 
 Episodes of brain hypoxia are prevalent and there appears to be a linear relationship 
between increased MAP and PbtO2 in adult human HIBI patients.  Perfusion within proximity of 
MAPOPT, as determined by PRx, may be associated with improved PbtO2.  Further physiologic 
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Figure 1: Scatter plots and locally weighted scatterplot smoothing function of PbtO2 (mmHg, 
black) and MAP (mmHg, cyan) versus time (hours, x-axis) for each patient.  The numbers in 
each respective box represent the corresponding patient and demographics displayed in table 1.   
 
Figure 2: Brain oxygen variables (PbtO2, rSO2 and SjvO2) on the y-axis vs. mean arterial 
pressure (MAP) in mmHg (x axis).  The dots are scatterplots between the two variables.  Light 
grey lines are locally weighted scatterplot smoothing function for each individual patient.  Black 
line is the overall regression line.  R2m is the marginal R
2.  R2c is the conditional R
2.   
 
Figure 3: Scatter plots of PRx over time for all patients. The solid lines are a locally weighted 
scatterplot smooth for each patient.  Values above the dashed line at a PRx of 0.3 represents a 
threshold of dysfunctional autoregulation.  Patients denoted by the colour cyan were survivors.  
Patients in black were non-survivors. 
 
Figure 4: Optimal MAP (MAPOPT), Lower Limit of Autoregulation (LLA) and Upper Limit of 
Autoregulation (ULA) over time for each patient.  The solid black line is MAPOPT.  The grey 
dashed lines represent the LLA and ULA.   
 
Figure 5: Scatter plot between PbtO2 and the difference between MAP and MAPOPT (MAPDIFF).  
The light grey dots are corresponding PbtO2 and MAPDIFF. The light grey solid lines are a locally 
weighted scatterplot smooth for each patient.  The solid black line is a predicted curve generated 
using a restricted cubic splines model.  Fractional polynomial (fp) regression confirmed there 
was a non-linear relationship between PbtO2 and MAPDIFF.  The best parameterization of 
MAPDIFF was using X
0.5 (fp 0.5).   
 
eFigure 1: Scatter plots between PbtO2 and temperature (left panel) or ETCO2 (right panel).  
The light grey dots are corresponding values of PbtO2 and the variable of interest. The light grey 
solid lines are a locally weighted scatterplot smooth for each patient.  
 
eFigure 2: Scatter plots between PRx and temperature (left panel) or ETCO2 (right panel).  The 
light grey dots are corresponding values of PbtO2 and the variable of interest. The light grey solid 
lines are a locally weighted scatterplot smooth for each patient. Values above the dashed grey 
line at a PRx of 0.3 represent dysfunctional autoregulation.  
 
 
 
 
